Skip to content
The Nexus
DossierENTITY

Axsome Therapeutics

Coverage of Axsome Therapeutics in the Nexus archive.

Earliest in view: May 12 · 22:00 UTCMost recent: May 12 · 22:00 UTC
Co-mentioned in this coverage
U.S. Food and Drug Administrationorganization1Auvelitytopic1Alzheimer's diseasetopic1Tracy Beth Hoegperson1FDA’s Center for Drug Evaluation and Researchorganization1
Recent coverage
  • HEALTHMay 12 · 22:00 UTCFOX NEWS
    New option available for Alzheimer’s patients as FDA approves expanded drug use

    The FDA has approved the expanded use of Auvelity for treating agitation in Alzheimer's disease patients. Auvelity was originally approved for major depressive disorder and has shown efficacy in two randomized trials. The approval represents a significant advancement in treating complications of Alzheimer's disease.

Axsome Therapeutics · Dossier · The Nexus